Answer
CAPVAXIVE uses 21 pneumococcal capsular polysaccharides conjugated to CRM197 carrier protein to elicit antibodies that enhance opsonisation, phagocytosis and killing of pneumococci, alongside a T-cell-dependent response supporting serotype-specific B-cell maturation.
Sources for this answer
- CAPVAXIVE solution for injection in pre-filled syringeMerck Sharp & Dohme (UK) Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 1Document updated
Sources checked